RT Journal Article
SR Electronic
T1 Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.19.22273872
DO 10.1101/2022.04.19.22273872
A1 Seekircher, Lisa
A1 Bánki, Zoltán
A1 Kimpel, Janine
A1 Rössler, Annika
A1 Schäfer, Helena
A1 Falkensammer, Barbara
A1 Bante, David
A1 Forer, Lukas
A1 Schönherr, Sebastian
A1 Harthaller, Teresa
A1 Sacher, Magdalena
A1 Ower, Cornelia
A1 Tschiderer, Lena
A1 Ulmer, Hanno
A1 Krammer, Florian
A1 Laer, Dorothee von
A1 Borena, Wegene
A1 Willeit, Peter
YR 2022
UL http://medrxiv.org/content/early/2022/04/21/2022.04.19.22273872.abstract
AB It is uncertain to which extent antibody and T-cell responses after vaccination against SARS-CoV-2 are associated with reduced risk of breakthrough infection and whether their measurement enhances risk prediction. We conducted a phase-4 open-label clinical trial in the pre-omicron era, enrolling 2,760 individuals aged ≥16 years 35±8 days after having received the second dose of BNT162b2 (baseline 15-21 May 2021). Over a median 5.9-month of follow-up, we identified incident SARS-CoV-2 breakthrough infections using weekly antigen tests, a confirmatory PCR test, and/or serological evidence for incident infection. We quantified relative risks adjusted for age, sex, and prior SARS-CoV-2 infection for different immunological parameters and assessed improvements in risk discrimination. In contrast to the T-cell response, higher plasma levels of binding antibodies and antibodies in a surrogate neutralization assay were associated with reduced risk of breakthrough infection. Furthermore, assessment of anti-spike IgG levels enhanced prediction of breakthrough infection and may therefore be a suitable measurable correlate of protection in practice.Competing Interest StatementDB declares to hold stocks of Pfizer. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. FK has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures, Merck and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. PW reports personal fees from Pfizer outside the submitted work. The other authors declare no competing interests.  Clinical TrialEudraCT no. 2021-002030-16Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Medical University of Innsbruck gave ethical approval for this work (no. 1168/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on COVID-19 cases in the district of Schwaz, Tyrol, in Austria is publicly available (data.gv.at - Open Data Oesterreich). Tabular data on the Shieldvacc-2 cohort can be requested from the corresponding authors by researchers who submit a methodologically sound proposal (including a statistical analysis plan); participant-level data on the Shieldvacc-2 cohort cannot be shared due to regulatory restrictions.